跳至主要内容
临床试验/NCT03117348
NCT03117348已完成不适用

Gradual Versus Immediate Goal-dose Enteral Nutrition in Abdominal Surgery Patients: A Clinical Randomized Controlled Trial

Jinling Hospital, China1 个研究点 分布在 1 个国家目标入组 411 人开始时间: 2017年4月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
411
试验地点
1
主要终点
Morbidity of infection

研究概览

简要总结

Patients will be randomized to Gradual or immediate Goal-dose EN group at day 3 after abdominal surgery. Patients will receive Goal-dose EN gradually or immediately after abdominal surgery. Both groups will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital. The primary and secondary outcomes will be collected.

详细描述

Patients after abdominal surgery will receive enteral nutrition for 2 days, if she/he can tolerate 30% of goal-dose EN, then she/he will be randomized to Gradual or immediate Goal-dose EN group at day 3. Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both groups will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first. The primary and secondary outcomes will be collected.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent of patients or their legal representatives to participate in this study.
  • patients undergoing selective operation without trauma
  • patients following medium or major abdominal surgery
  • NRS 2002≥ 3

排除标准

  • Psychiatric disorders
  • Pregnancy or breast-feeding women
  • Malnutrition
  • Weight loss >10%-15% in 6 months
  • SGA score with stage C
  • Albumin < 30g/L
  • Unstable vital signs or unstable hemodynamics (such as systolic blood pressure < 90 mmHg or mean arterial pressure < 70 mmHg after rapid 500 ml crystal or 200 ml gel infusion, or the 50% increase of vascular active drug infusion rate in an hour, etc)
  • Refuse to participate in the study
  • Mortality rates expected to more than 50% in 6 months with malignant or irreversibility diseases
  • Cancer in terminal stage or
  • HIV positive at end-stage or CD4 < 50/mm3
  • Cardiopulmonary resuscitation (CPR) before cardiac arrest and nervous system function not fully recovery
  • Four levels of physical activity of the patients defined by New York heart association
  • Rely on breathing machine because of chronic diseases
  • Life expectancy less than 24 hours of dying patients
  • Refractory shock to meet any of the following article
  • The infusion rate of dopamine > 15 ug/kg/min
  • The infusion rate of dobutamine > 15 ug/kg/min
  • The infusion rate of epinephrine and norepinephrine > 30 ug/min
  • The infusion rate of phenylephrine > 50 ug/min
  • The infusion rate of milrinone > 0.5 ug/kg/min
  • The infusion rate of vasopressin > 0.04 U/min
  • Inter aortic ballon pump (IABP)
  • Hepatic insufficiency (alanine/aspartate transaminase/bilirubin 200% above normal range)
  • Renal insufficiency(creatinine 200% above normal range)
  • Metabolic diseases(hyperthyroidism/ hypothyroidism, adrenal cortex disorders)
  • EN can not reach 30% of target energy in 48 hours after surgery
  • Burn area exceeding 20% of the patient's body surface
  • Autoimmune diseases or immune dysfunction or history of organ transplantation
  • International standardization ratio (INR) more than 3.0 or platelet count < 30000 cells/mm3 or other hemorrhagic diathesis
  • Intracranial hemorrhage one month before enrolment
  • General contraindications to infusion therapy or history of severe allergy against ingredients of enteral and parenteral nutrition
  • Has already participated in another clinical trial
  • Has started to nutritional support therapy before enrolment
  • Diabetes mellitus (anamnestic and/or under medical treatment)

结局指标

主要结局

Morbidity of infection

时间窗: From date of randomization until the date of infection from any cause, assessed up to 2 months.

Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.

次要结局

  • Laboratory examination(At the date of patients enrollment and after intervention, assessed up to 2 months.)
  • Length of stay in hospital(From date of operation until the date of patients discharged from hospital, assessed up to 12 months.)
  • Mortality(From date of randomization until the date of death, assessed up to 2 months after patients discharged from hospital.)
  • Actual calories intake(During the intervention, assessed up to 2 months.)
  • Scale the frequency of gastrointestinal intolerance(During the intervention, assessed up to 2 months.)

研究者

发起方
Jinling Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wang Xinying

Professor

Jinling Hospital, China

研究点 (1)

Loading locations...

相似试验

Gradual Versus Immediate Goal-dose Enteral Nutrition... | 临床试验